Roche launches new Elecsys AMH test for fertility

Roche has announced the European launch of its new Elecsys Anti-Mullerian Hormone (AMH) blood test, which has received CE Mark approval.

The fully-automated AMH test is designed for use in assessing a woman's ovarian reserve in order to gauge fertility levels. It can be measured at any time during the menstrual cycle and is a superior indicator of ovarian reserve as compared to follicle-stimulating hormones or estradiol.

Roche's new product also offers more standardised results than the use of ultrasound, whereby the result is often dependent on the operator or clinic.

Elecsys AMH is intended to be used in combination with a new human recombinant follicle-stimulating hormone treatment currently in phase III development at Ferring Pharmaceuticals.

Roland Diggelmann, chief operating officer of Roche Diagnostics, said: "The introduction of our Elecsys AMH test will enable healthcare professionals to incorporate AMH testing into routine clinical practice, while getting more reliable results faster than conventional protocols and manual AMH assays."

The firm offers a wide range of diagnostic tools, launching its new automated Cobas 6800/8800 molecular diagnostic systems earlier this month.